The mitotic serine threonine kinase, <i>Aurora-2</i>, is a potential target for drug development in human pancreatic cancer
Sangeeta Rojanala, David J. Bearss(Unknown)
Cited by 78
Related Papers
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
|Cancer Cell|2013|302
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
|British Journal of Cancer|2011|28
A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies
|Molecular Cancer Therapeutics|2007|2
Targeting Pim Kinases in Hematological Malignancies.
|Blood|2007|1
Abstract B272: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma
|Molecular Cancer Therapeutics|2009|0